Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014

# $MnFe_2O_4@NH_2@2AB-Ni:$ A novel, highly active, stable and magnetically recoverable nanocatalyst and use of this heterogeneous catalyst in green synthesis of spirooxindoles in water

H. Naeimi,<sup>a</sup> Z. Rashid,<sup>a</sup> A.-H. Zarnani,<sup>b</sup> and R. Ghahremanzadeh<sup>\*c</sup>

<sup>a</sup>Department of Organic Chemistry, Faculty of Chemistry, University of Kashan, Kashan, 87317, I.R. Iran.

<sup>b</sup>Reproductive Immunology Research Center, Avicenna Research Institute, (ACECR), Tehran, Iran.

<sup>c</sup>Nanobiotechnology Research Center, Avicenna Research Institute, (ACECR), Tehran, Iran.

E-mail: r.ghahremanzadeh@avicenna.ac.ir

### SUPPORTING INFORMATION

Page	List of contents	Page
1	<sup>13</sup> C NMR of <b>8a</b>	23
2-9	<sup>1</sup> H NMR of <b>8b</b>	24
10	<sup>13</sup> C NMR of <b>8b</b>	25
11	<sup>1</sup> H NMR of <b>8c</b>	26
12	<sup>13</sup> C NMR of <b>8c</b>	27
13	<sup>1</sup> H NMR of <b>8d</b>	28
14	<sup>13</sup> C NMR of <b>8d</b>	29
15	<sup>1</sup> H NMR of <b>8e</b>	30
16	<sup>13</sup> C NMR of <b>8e</b>	31
17	<sup>1</sup> H NMR of <b>8f</b>	32
18	<sup>13</sup> C NMR of <b>8</b> f	33
19	<sup>1</sup> H NMR of <b>8g</b>	34
20	<sup>13</sup> C NMR of <b>8g</b>	35
21	<sup>1</sup> H NMR of <b>8h</b>	36
22	<sup>13</sup> C NMR of <b>8h</b>	37
	Page   1   2-9   10   11   12   13   14   15   16   17   18   19   20   21   22	Page List of contents   1 <sup>13</sup> C NMR of 8a   2-9 <sup>1</sup> H NMR of 8b   10 <sup>13</sup> C NMR of 8b   11 <sup>1</sup> H NMR of 8c   12 <sup>13</sup> C NMR of 8c   13 <sup>1</sup> H NMR of 8c   14 <sup>13</sup> C NMR of 8d   15 <sup>1</sup> H NMR of 8e   16 <sup>13</sup> C NMR of 8e   17 <sup>1</sup> H NMR of 8f   18 <sup>13</sup> C NMR of 8f   19 <sup>1</sup> H NMR of 8g   20 <sup>13</sup> C NMR of 8g   21 <sup>1</sup> H NMR of 8h

#### **Experimental Part**

General. The chemicals used in this work were obtained from Fluka and Merck and were used without purification. Melting points were measured on an Electrothermal 9200 apparatus. IR spectra were recorded as KBr pellets on a Perkin-Elmer 781 spectrophotometer and an Impact 400 Nicolet FT-IR spectrophotometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a BRUKER DRX-300 AVANCE spectrometer at 300.13 and 75.47 MHz. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on solutions in DMSO- $d_6$  using tetramethylsilane as internal reference. X-ray diffraction (XRD) pattern of the as-synthesized material was obtained using a Holland Philips Xpert X-ray powder diffraction (XRD) diffractometer (CuK, radiation,  $\lambda$ = 0.154056 nm), at a scanning speed of 2°/min from 10° to 100° (20). The nanocatalyst was determined using a KYKY EM-3200 Scanning Electron Microscope (SEM) operated at a 26 kV accelerating voltage. Thermogravimetric/differential thermal analyses (TG/DTA) was performed on a Thermal Analyzer with a heating rate of 20 °C min<sup>-1</sup> over a temperature range of 25-800 °C under flowing compressed N<sub>2</sub>. The content of nickel in the heterogenized catalyst was determined by VISTA-PRO, CCD simultaneous ICP analyser. The purity determination of the substrates and reaction monitoring were accomplished by TLC on silica-gel polygram SILG/UV 254 plates (from Merck Company).

#### Typical procedure for the preparation of spirooxindoles 4(a-f) and 8(a-h).

A mixture of isatin 1 (1 mmol), cyclohexane-1,3-dione 2 (1 mmol), 2,6diaminopyrimidin-4(3*H*)-one 3 or barbituric acid 7 (1 mmol), catalyst (10 mg) and water (5 mL) was added in a round-bottomed flask and stirred at 90 °C. After completion of the reaction (monitored by TLC) the catalyst was easily separated from the reaction mixture with an external magnet. After separation of catalyst, the reaction mixture was filtered and the precipitate washed with water and recrystallized by EtOH to afford the pure product.

2'-Amino-1-methyl-8',9'-dihydro-3'*H*-spiro[indoline-3,5'-pyrimido[4,5*b*]quinoline]-2,4',6'(7'*H*,10'*H*)-trione (4a).



Cream powder (79%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3438, 3288, 2933, 1677, 1652. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_H$  (ppm) 1.79 (2H, brs, CH<sub>2</sub>), 2.03 (2H, brs, CH<sub>2</sub>), 2.52 (2H, brs, CH<sub>2</sub>), 3.04 (3H, s, NCH<sub>3</sub>), 6.40 (2H, s, NH<sub>2</sub>), 6.75-7.07 (4H, m, H-Ar), 9.55 (1H, s, NH), 10.12 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_C$  (ppm) 21.2, 26.6, 27.3, 37.5, 48.4, 91.8, 106.8, 110.5, 121.4, 122.7, 127.3, 136.6, 145.1, 153.8, 154.4, 154.6, 160.4, 179.5, 193.4.

2'-Amino-1-methyl-5-nitro-8',9'-dihydro-3'*H*-spiro[indoline-3,5'-pyrimido[4,5-*b*] quinoline]-2,4',6'(7'*H*,10'*H*)-trione (4b).



Cream powder (80%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3299, 3167, 2944, 1688, 1669. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_H$  (ppm) 1.81-1.82 (2H, m, CH<sub>2</sub>), 2.07-2.11 (2H, m, CH<sub>2</sub>), 2.55-2.59 (2H, m, CH<sub>2</sub>), 3.16 (3H, s, NCH<sub>3</sub>), 6.53 (2H, s, NH<sub>2</sub>), 7.02-8.17 (3H, m, H-Ar), 9.80 (1H, s, NH), 10.28 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_C$  (ppm) 21.0, 26.9, 27.2, 37.2, 48.5, 90.8, 106.8, 109.4, 117.8, 125.2, 137.5, 142.3, 151.4, 154.1, 154.9, 155.7, 160.6, 180.3, 193.9.

2'-Amino-8',8'-dimethyl-8',9'-dihydro-3'*H*-spiro[indoline-3,5'-pyrimido[4,5*b*]quinoline] -2,4',6'(7'*H*,10'*H*)-trione (4c).



Cream powder (96%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3334, 3189, 2938, 1697, 1655. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_H$  (ppm) 0.90 (3H, s, CH<sub>3</sub>), 0.98 (3H, s, CH<sub>3</sub>), 1.82-2.08 (2H, m, CH<sub>2</sub>), 2.32-2.50 (2H, m, CH<sub>2</sub>), 6.35 (2H, s, NH<sub>2</sub>), 6.57-6.99 (4H, m, H-Ar), 9.45 (1H, s, NH), 9.92 (1H, s, NH), 10.24 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_C$  (ppm) 26.9, 28.9, 32.3, 48.8, 51.0, 92.1, 108.1, 109.3, 120.6, 122.8, 127.0, 137.3, 143.6, 152.2, 153.9, 154.5, 160.5, 180.7, 193.1.

2'-Amino-5-bromo-8',8'-dimethyl-8',9'-dihydro-3'*H*-spiro[indoline-3,5'pyrimido[4,5-*b*] quinoline]-2,4',6'(7'*H*,10'*H*)-trione (4d).



Cream powder (94%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3416, 3164, 2959, 1701, 1645. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_H$  (ppm) 0.91 (3H, s, CH<sub>3</sub>), 0.97 (3H, s, CH<sub>3</sub>), 1.88-2.06 (2H, m, CH<sub>2</sub>), 2.41 (2H, brs, CH<sub>2</sub>), 6.42 (2H, s, NCH<sub>2</sub>), 6.54-7.15 (3H, m, H-Ar), 9.55 (1H, s, NH), 10.12 (1H, s, NH), 10.31 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_C$  (ppm) 27.3, 28.5, 32.3, 49.2, 50.9, 91.5, 108.7, 110.0, 112.2, 125.4, 129.7, 139.8, 143.2, 152.8, 154.0, 154.7, 160.5, 180.3, 193.3.

2'-Amino-8',8'-dimethyl-5-nitro-8',9'-dihydro-3'*H*-spiro[indoline-3,5'pyrimido[4,5-*b*] quinoline]-2,4',6'(7'*H*,10'*H*)-trione (4e).



Cream powder (93%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3427, 3185, 2923, 1720, 1662. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_H$  (ppm) 0.92 (3H, s, CH<sub>3</sub>), 0.97 (3H, s, CH<sub>3</sub>), 1.90-2.06 (2H, m, CH<sub>2</sub>), 2.47 (2H, brs, CH<sub>2</sub>), 6.49 (2H, s, NH<sub>2</sub>), 6.80-8.03 (3H, m, H-Ar), 9.70 (1H, s, NH), 10.38 (1H, s, NH), 10.79 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_C$  (ppm) 27.4, 28.3, 32.4, 49.0, 50.7, 91.0, 108.0, 108.3, 117.8, 125.1, 138.3, 141.7, 150.6, 153.5, 154.2, 154.8, 160.7, 181.4, 193.6.

2'-Amino-1,8',8'-trimethyl-8',9'-dihydro-3'*H*-spiro[indoline-3,5'-pyrimido[4,5-*b*] quinoline]-2,4',6'(7'*H*,10'*H*)-trione (4f).



Cream powder (92%); mp >300 °C dec. IR (KBr) ( $v_{max}$ / cm<sup>-1</sup>): 3330, 3176, 2940, 1691, 1652. <sup>1</sup>H NMR (300 MHz, DMSO- $d_6$ ):  $\delta_H$  (ppm) 0.89 (3H, s, CH<sub>3</sub>), 0.97 (3H, s, CH<sub>3</sub>), 1.81-2.05 (2H, m, CH<sub>2</sub>), 2.34-2.49 (2H, m, CH<sub>2</sub>), 3.05 (3H, s, NCH<sub>3</sub>), 6.40 (2H, s, NH<sub>2</sub>), 6.86-7.07 (4H, m, H-Ar), 9.51 (1H, s, NH), 10.13 (1H, s, NH). <sup>13</sup>C NMR (75 MHz, DMSO- $d_6$ ):  $\delta_C$  (ppm) 26.6, 27.0, 28.9, 32.3, 48.3, 50.9, 91.8, 106.8, 109.1, 121.4, 122.5, 127.3, 136.4, 145.1, 152.4, 153.9, 154.6, 160.4, 179.4, 193.1.

5'-Nitro-8,9-dihydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'-indoline]-2,2',4,6 (1*H*,3*H*,7*H*)-tetraone (8a)



Colorless crystals (92%); mp 278-280 °C dec. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3224, 1734, 1687, 1622. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 1.92 (2H, brs, CH<sub>2</sub>), 2.25 (2H, brs, CH<sub>2</sub>), 2.72 (2H, brs, CH<sub>2</sub>), 6.91 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 8.4 Hz, H-Ar), 8.05 (1H, s, H-Ar), 8.09 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 8.4 Hz, H-Ar), 11.11 (1H, s, NH), 11.16 (1H, s, NH), 12.31 (1H, brs, NH).<sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 20.0, 27.3, 37.0, 45.6, 88.6, 108.8, 113.6, 119.6, 126.1, 135.0, 142.3, 149.4, 150.9, 153.8, 162.2, 166.7, 179.0, 196.0.

5'-Nitro-2-thioxo-2,3,8,9-tetrahydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'indoline]-2',4,6(1*H*,7*H*)-trione (8b)



Colorless crystals (88%); mp >300 °C. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3363, 3060, 1717, 1683, 1622. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 1.69-1.75 (2H, brs, CH<sub>2</sub>), 2.25 (2H, brs, CH<sub>2</sub>), 2.72 (2H, brs, CH<sub>2</sub>), 6.91 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 6.0 Hz, H-Ar), 8.08-8.09 (2H, m, H-Ar), 11.20 (1H, s, NH), 12.48 (1H, s, NH), 13.75 (1H, brs, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 19.9, 27.3, 37.0, 45.6, 93.2, 108.8, 113.4, 119.9, 126.2, 134.4, 142.4, 150.9, 153.2, 159.8, 166.6, 174.1, 175.5, 195.9.

8,8-Dimethyl-8,9-dihydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'-indoline]-2,2',4,6(1*H*,3*H*,7*H*)-tetraone (8c)



White powder (96%); mp >300 °C. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3337, 3265, 1746, 1664, 1620. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 0.97 (3H, s, CH<sub>3</sub>), 1.03 (3H, s, CH<sub>3</sub>), 2.07, 2.10 (2H, AB<sub>q</sub>, <sup>3</sup>*J*<sub>AB</sub> = 15.9 Hz, CH<sub>2</sub>), 2.55, 2.66 (2H, AB<sub>q</sub>, <sup>3</sup>*J*<sub>AB</sub> = 17.6 Hz, CH<sub>2</sub>), 6.71 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 7.8 Hz H-Ar), 6.78 (1H, t, <sup>3</sup>*J*<sub>HH</sub> = 7.5 Hz H-Ar), 6.97 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 7.5 Hz, H-Ar), 6.08 (1H, t, <sup>3</sup>*J*<sub>HH</sub> = 7.5 Hz, H-Ar), 10.36(1H, s, NH), 11.01(1H, s, NH), 12.19(1H, brs, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 27.1, 28.2, 32.2, 45.5, 50.8, 89.6, 109.0, 113.6, 121.3, 123.3, 128.3, 134.0, 144.3, 149.4, 153.5, 161.9, 163.6, 178.2, 195.3.

## 5'-Bromo-8,8-dimethyl-8,9-dihydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'indoline]-2,2',4,6(1*H*,3*H*,7*H*)-tetraone (8d)



Colorless crystals (94%); mp >300 °C. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3162, 3121, 3049, 1739, 1724, 16581, 1617. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 0.99 (3H, s, CH<sub>3</sub>), 1.02 (3H, s, CH<sub>3</sub>), 2.09-2.21 (2H, m, CH<sub>2</sub>), 2.60 (2H, brs, CH<sub>2</sub>), 6.67 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 8.7 Hz, H-Ar), 7.23-7.25 (2H, m, H-Ar), 10.52 (1H, s, NH), 11.05 (1H, s, NH), 12.23 (1H, brs, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 27.5, 27.8, 32.2, 45.7, 50.8, 89.0, 110.7, 112.9, 113.0, 126.3, 130.9, 136.4, 143.7, 149.5, 153.7, 162.0, 164.0, 177.9, 195.6.

8,8-Dimethyl-5'-nitro-8,9-dihydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'indoline]-2,2',4,6(1*H*,3*H*,7*H*)-tetraone (8e)



Colorless crystals (96%); mp 290-292 °C dec. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3041, 2957, 1730, 1691, 1632. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 0.99 (3H, s, CH<sub>3</sub>), 1.02 (3H, s, CH<sub>3</sub>), 2.167 (2H, brs, CH<sub>2</sub>), 2.64 (2H, brs, CH<sub>2</sub>), 6.91 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 8.5 Hz, H-Ar), 8.04 (1H, s, H-Ar), 8.04-8.11 (1H, m, H-Ar), 11.10 (1H, s, NH), 11.16(1H, s, NH), 12.31(1H, brs, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 27.6, 27.7, 32.3, 45.6, 50.6, 88.5, 108.8, 112.6, 119.3, 126.1, 135.0, 142.3, 149.4, 151.0, 154.0, 162.2, 164.7, 178.9, 195.9.

## 5',8,8-Trimethyl-8,9-dihydrospiro[chromeno[2,3-*d*]pyrimidine-5,3'-indoline]-2,2',4,6 (1*H*,3*H*,7*H*)-tetraone (8f)



Colorless crystals (95%); mp 290-292 °C dec. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3368, 3178, 2962, 1724, 1680, 1622. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 0.98 (3H, s, CH<sub>3</sub>), 1.02 (3H, s, CH<sub>3</sub>), 2.06-2.21 (2H, m, CH<sub>2</sub>), 2.59-2.61 (2H, m, CH<sub>2</sub>), 3.66 (3H, s, CH<sub>3</sub>), 6.59 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 7.8 Hz, H-Ar), 7.81 (1H, s, H-Ar), 7.87 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 7.8 Hz, H-Ar), 10.26 (1H, s, NH), 11.01 (1H, s, NH), 12.19 (1H, s, NH) . <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 19.0, 21.1, 27.3, 28.0, 32.0, 45.5, 49.9, 89.7, 108.7, 113.6, 124.0, 128.5, 130.0, 134.1, 141.8, 149.5, 153.4, 161.9, 163.5, 178.1, 195.3.

5'-Bromo-8,8-dimethyl-2-thioxo-2,3,8,9-tetrahydrospiro[chromeno[2,3*d*]pyrimidine-5,3'-indoline]-2',4,6(1*H*,7*H*)-trione (8g)



Colorless crystals (90%); mp 280-282 °C. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3060, 2967, 1711, 1708. <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm H}$  (ppm) 0.99 (3H, s, CH<sub>3</sub>), 1.02 (3H, s, CH<sub>3</sub>), 2.16 (2H, brs, CH<sub>2</sub>), 2.60 (2H, brs , CH<sub>2</sub>), 6.67 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 8.1 Hz, H-Ar), 7.25 (1H, d, <sup>3</sup>*J*<sub>HH</sub> = 7.2 Hz, H-Ar), 7.33 (1H, s, H-Ar), 10.58 (1H, s, NH), 12.45 (1H, s, NH), 13.68 (1H, brs, NH). <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>):  $\delta_{\rm C}$  (ppm) 27.5, 27.8, 32.3, 45.7, 50.7, 93.7, 110.8, 112.9, 113.0, 126.6, 131.1, 135.8, 143.7, 153.1, 159.7, 164.0, 174.1, 177.4, 195.5.

8,8-Dimethyl-5'-nitro-2-thioxo-2,3,8,9-tetrahydrospiro[chromeno[2,3*d*]pyrimidine-5,3'-indoline]-2',4,6(1*H*,7*H*)-trione (8h)



Colorless crystals (92%); mp >300 °C. IR (KBr) ( $v_{max}$  /cm<sup>-1</sup>): 3383, 3337, 2962, 1730, 1684, 1627. <sup>1</sup>H NMR (300 MHz, DMSO- $d_6$ ):  $\delta_{\rm H}$  (ppm) 1.00-1.07 (6H, m, 2CH<sub>3</sub>), 2.17 (2H, brs, CH<sub>2</sub>), 2.63 (2H, brs, CH<sub>2</sub>), 6.93 (1H, d, <sup>2</sup> $J_{\rm AB}$  = 8.1 Hz, H-Ar), 8.09-8.14 (2H, m, H-Ar), 11.21 (1H, s, NH), 12.48 (1H, s, NH), 13.76 (1H, brs, NH) . <sup>13</sup>C NMR (75 MHz, DMSO- $d_6$ ):  $\delta_{\rm C}$  (ppm) 19.0, 27.6, 32.3, 45.5, 50.5, 56.5, 93.2, 108.9, 112.4, 119.7, 126.2, 134.4, 142.4, 150.9, 153.4, 160.0, 164.7, 174.2, 195.8.



 $^{1}$ H NMR of **4a** 



<sup>13</sup>C NMR of **4a** 



<sup>1</sup>H NMR of **4b** 



<sup>13</sup>C NMR of **4b** 











 $^{1}$ H NMR of **4d** 



 $^{13}$ C NMR of **4d** 



<sup>1</sup>H NMR of **4e** 



<sup>13</sup>C NMR of **4e** 











<sup>1</sup>H NMR of 8a



<sup>13</sup>C NMR of 8a



<sup>1</sup>H NMR of **8b** 



<sup>13</sup>C NMR of **8b** 



<sup>1</sup>H NMR of 8c



<sup>13</sup>C NMR of **8c** 



 $^{1}$ H NMR of **8d** 



<sup>13</sup>C NMR of **8d** 







<sup>13</sup>C NMR of **8e** 



<sup>1</sup>H NMR of **8f** 











<sup>13</sup>C NMR of **8g** 







